Sigilon is headquartered in Cambridge, Massachusetts.
Sigilon disclosed revenue of 13M USD for 2020 and 14M USD for 2019.
Sigilon is a life science company.
Sigilon was founded in 2015.
100 Binney Street, Suite 600,
Cambridge, Massachusetts
02142
United States,
(617) 336-7540
www.sigilon.com
Sigilon is a biopharmaceutical company that develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate-severe to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of the disease in patients with mucopolysaccharidosis type 1; and SIG-002 designed to replace islet cells for the treatment of type 1 diabetes. Sigilon was formed in 2015 and is based in Cambridge, Massachusetts.
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
